Pay in 4 interest-free payments of $5.21 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Watch the Recording What Youll Learn Shifts in payer perspectives on obesity as a lifestyle condition versus a chronic medical condition Payers GLP-1 coverage decisions and management strategies Updates on affordability concerns and price willing to pay for GLP-1s for obesity The influence of discontinuation rates on obesity GLP-1 coverage conversations The role of weight management vendor partnerships as part of obesity GLP-1 coverage strategies Payers preparedness for expanded GLP-1 indications and new medications entering the market Attendees will gain actionable strategies and insights to optimize their pharmacy benefit design for these high-impact medications in 2026 and beyond
Each peptide is selected for a precise purpose, for example, controlling appetite, improving tissue healing, or supporting sexual wellness
Side Effects Public Media is a health reporting collaboration based at WFYI in Indianapolis
Glycemic control deterioration occurs in patients with type 2 diabetes
